Last updated on July 2020

Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity Mortality and NT-proBNP Change in Patients With CCC

Brief description of study

The purpose of this study is to evaluate the effect of sacubitril/valsartan 200 mg BID compared with enalapril 10 mg BID, in addition to conventional heart failure (HF) treatment, in improving a hierarchical composite of cardiovascular (CV) events (i.e. CV death or the occurrence of first HF hospitalization) and causing a greater reduction in n terminal prohormone of brain natriuretic peptide (NT-proBNP, at Week 12 from Baseline) in participants with HF with reduced ejection fraction (HFrEF) caused by CCC.

Clinical Study Identifier: NCT04023227

Find a site near you

Start Over

Novartis Investigative Site

Rosario, Argentina
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.